AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25593121 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheter-directed thrombolysis
Number of subjects: 48
Study 23962386 — intervention group
Group type: EXPERIMENTAL
Intervention: Tightness of cuff during knee-extension exercises
Number of subjects: 0
Study 23962386 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin and subcutaneous fat thickness
Number of subjects: 0
Study 21106340 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed endotracheal suctioning (CES)
Number of subjects: 200
Study 21106340 — intervention group
Group type: COMPARATOR
Intervention: Open endotracheal suctioning (OES)
Number of subjects: 200
Study 20066964 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg
Number of subjects: 100
Study 20066964 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 200 mg
Number of subjects: 100
Study 20066964 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg with sucrose
Number of subjects: 100
Study 20066964 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 200 mg with sucrose
Number of subjects: 100
Study 20066964 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose with starch
Number of subjects: 100
Study 17185007 — intervention group
Group type: EXPERIMENTAL
Intervention: High impact anaerobic sprints
Number of subjects: 27
Study 17185007 — intervention group
Group type: COMPARATOR
Intervention: Low impact aerobic running
Number of subjects: 27
Study 17185007 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 27
Study 15083524 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (single-dose)
Number of subjects: 8
Study 15083524 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study 11435512 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-based cereal and nutritional counseling
Number of subjects: 418
Study 11435512 — intervention group
Group type: COMPARATOR
Intervention: Nutritional counseling alone
Number of subjects: 418
Study 11435512 — intervention group
Group type: COMPARATOR
Intervention: Visitation group (control for morbidity ascertainment)
Number of subjects: 418
Study 11435512 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 418
Study 9492730 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-closure of both visceral and parietal peritoneum (study group, n = 179)
Number of subjects: 361
Study 9492730 — intervention group
Group type: COMPARATOR
Intervention: Closure of both layers (control group, n = 182)
Number of subjects: 361
Study 11271231 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 540
Study 11271231 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A
Number of subjects: 540
Study 11271231 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506 (after conversion from cyclosporin A)
Number of subjects: 540
Study 3051072 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 189
Study 3051072 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 189
Study 3051072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 7964959 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN) started at 1 x 10(6) U/m2 SC three times per week, escalating to a maximum of 3 x 10(6) U/m2 SC three times per week for 6 months.
Number of subjects: 32
Study 7964959 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN)
Number of subjects: 32
Study 7964959 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 32
Study 282082 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner care
Number of subjects: 0
Study 282082 — intervention group
Group type: COMPARATOR
Intervention: Physician care
Number of subjects: 0
Study 31950527 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counseling support during the first 3 months after childbirth from 10 peers with successful breastfeeding experiences.
Number of subjects: 80
Study 31950527 — intervention group
Group type: COMPARATOR
Intervention: Routine education provided by health centers (Control).
Number of subjects: 80
Study 30689258 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN add‐on therapy
Number of subjects: 234
Study 30689258 — intervention group
Group type: COMPARATOR
Intervention: ETV monotherapy
Number of subjects: 234
Study 30689258 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN add‐on therapy in PEG‐IFN naive patients with HBsAg <4000 IU/mL and HBV DNA <50 IU/mL
Number of subjects: 234
Study 30689258 — intervention group
Group type: COMPARATOR
Intervention: ETV monotherapy in PEG‐IFN naive patients with HBsAg <4000 IU/mL and HBV DNA <50 IU/mL
Number of subjects: 234
Study 28198661 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation-based approach using Aid for Decision-Making in Occupation Choice (ADOC)
Number of subjects: 48
Study 28198661 — intervention group
Group type: COMPARATOR
Intervention: Impairment-based approach
Number of subjects: 48
Study 25670362 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg/day
Number of subjects: 0
Study 22820629 — intervention group
Group type: EXPERIMENTAL
Intervention: GameBike
Number of subjects: 36
Study 22820629 — intervention group
Group type: COMPARATOR
Intervention: Traditional stationary bikes
Number of subjects: 36
Study 21835287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon counterpulsation (IABC)
Number of subjects: 499
Study 21835287 — intervention group
Group type: EXPERIMENTAL
Intervention: Early revascularization (ERV)
Number of subjects: 499
Study 21835287 — intervention group
Group type: COMPARATOR
Intervention: Initial medical stabilization (IMS)
Number of subjects: 499
Study 20042788 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS (2 mA for 20 min)
Number of subjects: 20
Study 20042788 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (2 mA for 1 min)
Number of subjects: 20
Study 16753373 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg bicalutamide daily
Number of subjects: 3292
Study 16753373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3292
Study 16753373 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 3292
Study 15005441 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride mouthrinse with essential oils
Number of subjects: 153
Study 15005441 — intervention group
Group type: COMPARATOR
Intervention: Fluoride nonessential oils mouthrinse (positive control)
Number of subjects: 153
Study 15005441 — intervention group
Group type: COMPARATOR
Intervention: Essential oil nonfluoride mouthrinse (negative control)
Number of subjects: 153
Study 12199263 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 100
Study 9829605 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) supplementation (0.15 mg/kg/d) during total parenteral nutrition (TPN)
Number of subjects: 28
Study 9829605 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 28
Study 9829605 — intervention group
Group type: COMPARATOR
Intervention: None (control group receiving no rhGH)
Number of subjects: 28
Study 8067698 — intervention group
Group type: EXPERIMENTAL
Intervention: DDP (cisplatin)
Number of subjects: 22
Study 2688065 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (4 g)
Number of subjects: 44
Study 2688065 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone metasulphobenzoate (20 mg)
Number of subjects: 44
Study 5310209 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (100 mg twice daily for 20 days)
Number of subjects: 215
Study 5310209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 5310209 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 215
Study 31415194 — intervention group
Group type: EXPERIMENTAL
Intervention: Me & You intervention
Number of subjects: 709
Study 31415194 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 709
Study 28911287 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 160
Study 28911287 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine/Atropine
Number of subjects: 160
Study 25057991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative cervical dilatation
Number of subjects: 208
Study 25057991 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative cervical dilatation (Control)
Number of subjects: 208
Study 23389298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine (Gln)
Number of subjects: 0
Study 23389298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21778352 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 30 mg
Number of subjects: 10
Study 21778352 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 100 mg
Number of subjects: 10
Study 21778352 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 300 mg
Number of subjects: 10
Study 21778352 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 900 mg
Number of subjects: 10
Study 21778352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18623910 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant parathyroid hormone
Number of subjects: 0
Study 18623910 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 0
Study 18623910 — intervention group
Group type: COMPARATOR
Intervention: Bisphosphonates
Number of subjects: 0
Study 16495253 — intervention group
Group type: EXPERIMENTAL
Intervention: FPV 1,400 mg BID plus RTV 100 mg BID
Number of subjects: 42
Study 16495253 — intervention group
Group type: EXPERIMENTAL
Intervention: FPV 1,400 mg BID plus RTV 200 mg BID
Number of subjects: 42
Study 16495253 — intervention group
Group type: COMPARATOR
Intervention: FPV 700 mg BID plus RTV 100 mg BID
Number of subjects: 42
Study 12451441 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (200 mg)
Number of subjects: 8
Study 12451441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11482295 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized treatment simulation presentation
Number of subjects: 146
Study 11482295 — intervention group
Group type: COMPARATOR
Intervention: Standard presurgical consultation
Number of subjects: 146
Study 11482295 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment simulation group
Number of subjects: 146
Study 11482295 — intervention group
Group type: COMPARATOR
Intervention: Standard presurgical consultation group
Number of subjects: 146
Study 11482295 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall expectations related to psychological distress and gender
Number of subjects: 146
Study 9569113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejaculation (study group)
Number of subjects: 25
Study 9569113 — intervention group
Group type: COMPARATOR
Intervention: No ejaculation (control group)
Number of subjects: 25
Study 8308570 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soybean protein + soybean cotyledon fiber
Number of subjects: 21
Study 8308570 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soybean protein + cellulose
Number of subjects: 21
Study 8308570 — intervention group
Group type: COMPARATOR
Intervention: Casein + soybean cotyledon fiber
Number of subjects: 21
Study 8308570 — intervention group
Group type: COMPARATOR
Intervention: Casein + cellulose
Number of subjects: 21
Study 2737719 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 3234
Study 2737719 — intervention group
Group type: COMPARATOR
Intervention: Thiazide diuretics
Number of subjects: 3234
Study 4755182 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E(1)
Number of subjects: 0
Study 4755182 — intervention group
Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 0
Study 4755182 — intervention group
Group type: COMPARATOR
Intervention: Low concentrations of prostaglandins
Number of subjects: 0
Study 31084288 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic horse riding (20-week intervention)
Number of subjects: 12
Study 31030981 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-guided individualised nutritional support to reach protein and caloric goals
Number of subjects: 2088
Study 31030981 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital food
Number of subjects: 2088
Study 26888312 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion-focused imagery intervention
Number of subjects: 51
Study 26888312 — intervention group
Group type: COMPARATOR
Intervention: Control imagery condition
Number of subjects: 51
Study 27230437 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time medication monitoring (RTMM) with tailored SMS reminders
Number of subjects: 209
Study 27230437 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 209
Study 25190425 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory training 2x/week for 15 sessions
Number of subjects: 0
Study 25190425 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory training 3x/week for 15 sessions
Number of subjects: 0
Study 25190425 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 0
Study 22726281 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg once daily)
Number of subjects: 50
Study 22726281 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (75 mg twice daily)
Number of subjects: 50
Study 22726281 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 50
Study 19473334 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone administration after mail administration
Number of subjects: 447
Study 19473334 — intervention group
Group type: COMPARATOR
Intervention: Mail administration first
Number of subjects: 447
Study 19473334 — intervention group
Group type: COMPARATOR
Intervention: Telephone administration first
Number of subjects: 447
Study 17167262 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic candy with calcium
Number of subjects: 20
Study 17167262 — intervention group
Group type: COMPARATOR
Intervention: Acidic candy without calcium (control)
Number of subjects: 20
Study 14693633 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled mask ventilation
Number of subjects: 41
Study 14693633 — intervention group
Group type: COMPARATOR
Intervention: Circle system ventilation
Number of subjects: 41
Study 12476290 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine dipeptide (30 g i.v. from day +1 to day +14)
Number of subjects: 40
Study 10439748 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane/nitrous oxide/fentanyl (Group 1)
Number of subjects: 20
Study 10439748 — intervention group
Group type: COMPARATOR
Intervention: Propofol/fentanyl (Group 2)
Number of subjects: 20
Study 10439748 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 20
Study 7599546 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine combined with bupivacaine injected into the knee joint
Number of subjects: 45
Study 7599546 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet time of 0 minutes
Number of subjects: 45
Study 7599546 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet time of 8 minutes
Number of subjects: 45
Study 7599546 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet time of 16 minutes
Number of subjects: 45
Study 2238820 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic stockings (below-knee, elastic compression) for 12 months
Number of subjects: 140
Study 2238820 — intervention group
Group type: COMPARATOR
Intervention: Control group (no compression)
Number of subjects: 140
Study 393286 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 20
Study 393286 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 20
Study 31849085 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin infusion (8 g/dL of ascitic fluid; n = 40)
Number of subjects: 80
Study 31849085 — intervention group
Group type: COMPARATOR
Intervention: No albumin (n = 40)
Number of subjects: 80
Study 31849085 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin infusion
Number of subjects: 80
Study 30884808 — intervention group
Group type: EXPERIMENTAL
Intervention: SAx (Hydroxytyrosol 9.9 mg and Punicalagin 195 mg)
Number of subjects: 84
Study 28489212 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol group with exams requested according to the study protocol
Number of subjects: 405
Study 28489212 — intervention group
Group type: COMPARATOR
Intervention: Non-selectively requested exams group
Number of subjects: 405
Study 26417002 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoblastoma survivors
Number of subjects: 470
Study 26417002 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral RB survivors
Number of subjects: 470
Study 26417002 — intervention group
Group type: COMPARATOR
Intervention: Unilateral RB survivors
Number of subjects: 470
Study 26417002 — intervention group
Group type: COMPARATOR
Intervention: CCSS siblings
Number of subjects: 470
Study 23719552 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (37% of energy from fat and 50% of energy from carbohydrates)
Number of subjects: 12
Study 23719552 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (25% of energy from fat and 62% of energy from carbohydrates)
Number of subjects: 12
Study 23719552 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 12
Study 23719552 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 12
Study 21145053 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitors
Number of subjects: 4966
Study 21145053 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate
Number of subjects: 4966
Study 21145053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 4966
Study 21145053 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality studies on Ulinastatin
Number of subjects: 4966
Study 21145053 — intervention group
Group type: COMPARATOR
Intervention: Other outcomes
Number of subjects: 4966
Study 19122170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 0
Study 19122170 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 0
Study 19122170 — intervention group
Group type: COMPARATOR
Intervention: LDL-C
Number of subjects: 0
Study 17676693 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with bulimia nervosa
Number of subjects: 48
Study 17676693 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 48
Study 15377355 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-compound product (TCP) containing calcipotriol (50 microg g(‐1)) and betamethasone dipropionate (0.5 mg g(‐1)) applied once or twice daily
Number of subjects: 828
Study 15377355 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol (50 microg g(‐1)) applied twice daily
Number of subjects: 828
Study 15377355 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo) applied twice daily
Number of subjects: 828
Study 15377355 — intervention group
Group type: EXPERIMENTAL
Intervention: TCP applied once daily
Number of subjects: 828
Study 15377355 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol applied twice daily
Number of subjects: 828
Study 15377355 — intervention group
Group type: EXPERIMENTAL
Intervention: TCP applied twice daily
Number of subjects: 828
Study 11409676 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete implant stabilised oral prostheses (IG)
Number of subjects: 83
Study 11409676 — intervention group
Group type: EXPERIMENTAL
Intervention: New conventional complete dentures (CDG2)
Number of subjects: 83
Study 11409676 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures (CDG1)
Number of subjects: 83
Study 9686717 — intervention group
Group type: EXPERIMENTAL
Intervention: Gowned patients
Number of subjects: 223
Study 9686717 — intervention group
Group type: COMPARATOR
Intervention: Ungowned patients
Number of subjects: 223
Study 9744214 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-procedural education/counselling program
Number of subjects: 130
Study 9744214 — intervention group
Group type: COMPARATOR
Intervention: Standard ward care (comparison group)
Number of subjects: 130
Study 1863741 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine sulfate
Number of subjects: 32
Study 1863741 — intervention group
Group type: COMPARATOR
Intervention: Protamine chloride
Number of subjects: 32
Study 6685644 — intervention group
Group type: EXPERIMENTAL
Intervention: LMP/FVP
Number of subjects: 230
Study 6685644 — intervention group
Group type: EXPERIMENTAL
Intervention: LMFP/ADM
Number of subjects: 230
Study 6685644 — intervention group
Group type: EXPERIMENTAL
Intervention: low-dose chemotherapy (lmfp)
Number of subjects: 230
Study 6685644 — intervention group
Group type: EXPERIMENTAL
Intervention: bony metastases as dominant lesion
Number of subjects: 230
Study 30541754 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0
Study 30541754 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 30145971 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit-lesion-only PCI
Number of subjects: 706
Study 30145971 — intervention group
Group type: COMPARATOR
Intervention: Multivessel PCI
Number of subjects: 706
Study 26303102 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 672
Study 26303102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study 24472854 — intervention group
Group type: COMPARATOR
Intervention: Sequential intervention (n=1736)
Number of subjects: 5055
Study 24472854 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous intervention (n=1638)
Number of subjects: 5055
Study 24472854 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 5055
Study 23350190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon
Number of subjects: 0
Study 23350190 — intervention group
Group type: EXPERIMENTAL
Intervention: Amixin
Number of subjects: 0
Study 23350190 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridostin
Number of subjects: 0
Study 23350190 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin in combination with cycloferon
Number of subjects: 0